AMLX Q2 2023 Earnings — Amylyx Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMLXAmylyx Pharmaceuticals, Inc.

$1B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$98M

Gross Profit

$93M94.3% margin

Operating Income

$20M20.6% margin

Net Income

$22M22.5% margin

EPS (Diluted)

$0.31

QoQ Revenue Growth

+37.5%

Cash Flow

Operating Cash Flow

$9M

Free Cash Flow

$8M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$454M

Total Liabilities

$67M

Stockholders' Equity

$386M

Cash & Equivalents

$248M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$98M	$0	—
Gross Profit	$93M	$0	—
Operating Income	$20M	-$54M	+137.2%
Net Income	$22M	-$54M	+140.8%